



NDA 020592 S-060 S-061
NDA 021086 S-038 S-039

**SUPPLEMENT APPROVAL
RELEASE REMS REQUIREMENT**

Eli Lilly and Company
Attention: Kevin Sheehan, MS, Pharm.D.
Manager, Global Regulatory Affairs, US
Lilly Corporate Center
Indianapolis, IN 46285

Dear Dr. Sheehan:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received March 15, 2011 (S-061, S-039) and March 16, 2011 (S-060, S-038), submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zyprexa (olanzapine) Tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg, and Zyprexa Zydis (olanzapine) Orally Disintegrating Tablets 5 mg, 10 mg, 15 mg, and 20 mg.

S-060 and S-038

We acknowledge receipt of your amendments to S-060 and S-038 dated May 31, 2011.

We also refer to our letter dated February 14, 2011, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Zyprexa (olanzapine) Tablets and Zyprexa Zydis (olanzapine) Orally Disintegrating Tablets. This information pertains to patient survey results that showed that patients did not understand the most important safety risks associated with the use of Zyprexa (olanzapine) Tablets and Zyprexa Zydis (olanzapine) Orally Disintegrating Tablets.

These supplemental new drug applications provide for revisions to the Medication Guide for Zyprexa (olanzapine) Tablets and Zyprexa Zydis (olanzapine) Orally Disintegrating Tablets, consistent with our letter dated February 14, 2011.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

S-061 and S-039

We acknowledge receipt of your risk evaluation and mitigation strategy (REMS) assessment dated September 17, 2010.

These supplemental new drug applications propose to eliminate the requirement for the approved risk evaluation and mitigation strategy (REMS) for Zyprexa (olanzapine) Tablets and Zyprexa Zydis (olanzapine) Orally Disintegrating Tablets.

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

The REMS for Zyprexa (olanzapine) Tablets and Zyprexa Zydis (olanzapine) Orally Disintegrating Tablets was originally approved on March 19, 2009 and a REMS modification was approved on December 4, 2009. The REMS consists of a Medication Guide and a timetable for submission of assessments of the REMS.

You propose that FDA no longer require a REMS for Zyprexa (olanzapine) Tablets and Zyprexa Zydis (olanzapine) Orally Disintegrating Tablets.

We have determined that maintaining the Medication Guide as part of the approved labeling is adequate to address the serious and significant public health concern and meets the standard in 21 CFR 208.1. Therefore, it is no longer necessary to include the Medication Guide as an element of the approved REMS to ensure that the benefits of Zyprexa (olanzapine) Tablets and Zyprexa Zydis (olanzapine) Orally Disintegrating Tablets outweigh their risks.

Therefore, we agree with your proposal and a REMS for Zyprexa (olanzapine) Tablets and Zyprexa Zydis (olanzapine) Orally Disintegrating Tablets is no longer required.

We remind you that the Medication Guide will continue to be part of the approved labeling in accordance with 21 CFR 208.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Keith Kiedrow, Pharm.D., Senior Regulatory Project Manager, at (301) 796-1924.

Sincerely,

{See appended electronic signature page}

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS P LAUGHREN
06/21/2011